Smith, K.A.; Majeed, A.W.; Mangnall, D.
April 2003
Gut;Apr2003 Supplement 1, Vol. 52, pA104
Academic Journal
Introduction: An increase in the activity of the urokinase like plasminogen activator (uPA) has been recorded almost immediately after partial hepatectomy in rats but not confirmed in humans. Aims: To determine whether changes in uPA activity occur in humans immediately after hepatectomy. Methods: Samples of liver tissue were taken from the liver before resection was commenced (Sample 1). Further samples were taken from the resected and remnant liver tissue at completion of resection (Samples 2 and 3) and finally just before wound closure (Samples 4 and 5). These were homogenised in MOPS buffered sucrose containing appropriate proteases inhibitors, uPA activity was determined fluorometrically by the hydrolysis of Z-gly-gly-arg-AMC substrate in washed membrane fractions prepared from the homogenate. Zymography was performed using standard techniques. The surgeon estimated percentage hepatic parenchyma resected. Results: 18 patients undergoing hepatic resection were studied. Median (range) age was 67.5 (24-78) years. Percentage liver parenchyma resected (median, range)was 35% (10-80%). Mean (SD) uPA activity in the samples were calculated and compared between patients having < 50% hepatectomy (n = 11 ) with those having > 50% hepatectomy (n = 7) as shown in the table. Conclusion: Increases in uPA activity occur in the remnant liver in humans after major (50% or more) hepatectomy and may represent the first stage in the degradation of extracellular matrix as a prelude to regeneration.


Related Articles

  • Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase. Mochizuki, Yasushi; Tsuda, Satoshi; Kanetake, Hiroshi; Kanda, Shigeru // Oncogene;10/10/2002, Vol. 21 Issue 46, p7027 

    Presents a study that examined the signal transduction pathways involved in the regulation of urokinase-type plasminogen activator (uPA) production by fibroblast growth factor (FGF)-2 treatment. Upregulation of uPA production in murine brain capillary endothelial cells; Enhancement of...

  • Correction.  // Gut;Sep2015, Vol. 64 Issue 9, p1465 

    A correction to the article "The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation" that was published in a previous issue is presented.

  • Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Kuhn, W; Schmalfeldt, B; Pache, L; Berger, U; Ulm, K; Harbeck, N; Späthe, K; Dettmar, P; Höfler, H; Jänicke, F; Schmitt, M; Graeff, H // British Journal of Cancer;4/1/99, Vol. 79 Issue 11/12, p1746 

    Strong evidence has accumulated on the prognostic value of tumour-associated proteolytic factors in patients afflicted with solid malignant tumours, including advanced ovarian cancer. We evaluated the prognostic impact of the protease urokinase plasminogen activator (uPA) and its inhibitor PAI-1...

  • Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: Comparison in a decision analysis model. Olvey, Eleanor L.; Skrepnek, Grant H.; Nolan Jr., Paul E. // American Journal of Health-System Pharmacy;8/1/2008, Vol. 65 Issue 15, p1435 

    Purpose. The cost-effectiveness of urokinase and alteplase for the treatment of acute peripheral artery disease (PAD) was compared using decision analysis. Methods. A literature-based decision model to evaluate cost-effectiveness was constructed using a base case of a 65-year-old man with acute...

  • Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels. Gustafsson, Anna; Ajeti, Vjosa; Ljunggren, Lennart // Biomarker Insights;2011, Issue 6, p119 

    The soluble urokinase plasminogen activator receptor (suPAR) has been detected in blood, plasma, serum, urine, ovarian cystic fluid, and cerebrospinal fluid. Elevated suPAR levels in plasma have been associated with negative outcomes in various diseases, such as bacteremia, sepsis, SIRS,...

  • A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Eefting, Daniel; Seghers, Leonard; Grimbergen, Jos M.; De Vries, Margreet R.; De Boer, Hetty C.; Lardenoye, Jan-Willem H.P.; Jukema, J. Wouter; Bockel, J. Hajo van; Quax, Paul H.A. // Cardiovascular Research;Nov2010, Vol. 88 Issue 2, p367 

    Aims Matrix metalloproteinases (MMP) and plasminogen activator (PA)/plasmin-mediated proteolysis, especially at the cell surface, play important roles in matrix degeneration and smooth muscle cell migration, which largely contributes to vein graft failure. In this study, a novel hybrid protein...

  • Suppression of Keratinocyte Proliferation by Plasminogen Activator Inhibitor-2. Hibino, Toshihiko; Matsuda, Yasushi; Takahashi, Tadahito; Goetinck, Paul F. // Journal of Investigative Dermatology;Jan1999, Vol. 112 Issue 1, p85 

    We have previously shown that urokinase plasminogen activator (uPA) stimulates the growth of human keratinocytes in culture. For this effect, uPA activity is essential to generate the active amino terminal fragment, by an autolytic process. Our findings indicated further that inhibition of uPA...

  • Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice. Qian, H. S.; Gu, J.-M.; Liu, P.; Kauser, K.; Halks-Miller, M.; Vergona, R.; Sullivan, M. E.; Dole, W. P.; Deng, G. G. // Gene Therapy;Feb2008, Vol. 15 Issue 3, p224 

    Vessel wall inflammation and matrix destruction are critical to abdominal aortic aneurysm (AAA) formation and rupture. We have previously shown that urokinase plasminogen activator (uPA) is highly expressed in experimental AAA and is essential for AAA formation and expansion. In this study, we...

  • Differential Roles of uPAR in Peritoneal Ovarian Carcinomatosis. Al-Hassan, Nada N.; Behzadian, Ali; Caldwell, Ruth; Ivanova, Vessela S.; Syed, Viqar; Motamed, Kouros; Said, Neveen A. // Neoplasia;Apr2012, Vol. 14 Issue 4, p259 

    Epithelial ovarian cancer is the fourth leading cause of death from gynecologic malignancies in the United States. Most cases are diagnosed at late stages, with the solid tumor masses growing as peritoneal implants, or floating within the ascitic fluid (peritoneal ovarian carcinomatosis)....


Read the Article


Sign out of this library

Other Topics